Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orally
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioavailability
Conditions
Bioavailability, Healthy Subjects
Trial Timeline
May 1, 2015 → Jul 1, 2015
NCT ID
NCT02446171About Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orally
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orally is a phase 1 stage product being developed by AstraZeneca for Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT02446171. Target conditions include Bioavailability, Healthy Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02446171 | Phase 1 | Completed |
Competing Products
20 competing products in Bioavailability